BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is an American biotechnology enterprise that develops and commercializes innovative biopharmaceutical products for the treatment of serious rare and ultra-rare genetic diseases. The company researches, develops, and markets enzyme replacement therapies and gene therapies targeting underlying genetic conditions and metabolic disorders. Its principal business activities encompass biopharmaceutical research, clinical development, manufacturing operations, and global commercialization of specialized therapeutics. BioMarin's main revenue drivers are global commercial sales of approved proprietary drugs for rare genetic disorders. As a pioneer in rare disease therapeutics, the company holds a leading market position within its specialized healthcare sector. Headquartered in San Rafael, California, United States, BioMarin Pharmaceutical is publicly listed and traded on NASDAQ.
19 of the funds FundTelligence covers report a position in BioMarin Pharmaceutical.
- Legal name
- BioMarin Pharmaceutical Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 19
Funds holding BioMarin Pharmaceutical
- DNB Bioteknologi — DNB · 5.31 % (full portfolio disclosed, September 2026)
- DWS Invest CROCI US — DWS · 2.69 % (full portfolio disclosed, June 2026)
- DNB Health Care — DNB · 1.58 % (full portfolio disclosed, September 2026)
- DNB Global — DNB · 1.07 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.7 % (full portfolio disclosed, October 2026)
- Fondsfinans Global Helse — Fondsfinans · 0.57 % (full portfolio disclosed, October 2026)
- Swedbank Robur Healthcare — Swedbank · 0.53 % (full portfolio disclosed, October 2026)
- Nordea Global High Yield Sustainable Stars Bond Fund — Nordea Funds · 0.33 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 19 funds holding it.